TL-895 for Primary Myelofibrosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Primary Myelofibrosis+3 More
TL-895 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug, KRT-232, to see if it can help treat myelofibrosis, a bone marrow disorder.

Eligible Conditions
  • Primary Myelofibrosis
  • Post PV MF

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Primary Myelofibrosis

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 56 Days

24 Weeks
Phase 2 - Spleen response rate for each cohort
Total Symptom Score (TSS)
56 Days
Phase 1b - The MTD/MAD and RP2D of TL-895 in combination with KRT-232 in patients with R/R MF (Cohort 1 and Cohort 2)

Trial Safety

Safety Progress

1 of 3

Other trials for Primary Myelofibrosis

Trial Design

5 Treatment Groups

Cohort 2 (R/R MF), Dose Level 1
1 of 5
Cohort 1 (R/R MF), Dose Level 2
1 of 5
Cohort 2 (R/R MF), Dose Level 2
1 of 5
Cohort 1 (R/R MF), Dose Level 1
1 of 5
Cohort 3 (JAKi Intolerant MF)
1 of 5
Experimental Treatment

116 Total Participants · 5 Treatment Groups

Primary Treatment: TL-895 · No Placebo Group · Phase 1 & 2

Cohort 2 (R/R MF), Dose Level 1Experimental Group · 2 Interventions: TL-895, KRT-232 · Intervention Types: Drug, Drug
Cohort 1 (R/R MF), Dose Level 2Experimental Group · 2 Interventions: TL-895, KRT-232 · Intervention Types: Drug, Drug
Cohort 2 (R/R MF), Dose Level 2Experimental Group · 2 Interventions: TL-895, KRT-232 · Intervention Types: Drug, Drug
Cohort 1 (R/R MF), Dose Level 1Experimental Group · 2 Interventions: TL-895, KRT-232 · Intervention Types: Drug, Drug
Cohort 3 (JAKi Intolerant MF)
Drug
Experimental Group · 1 Intervention: KRT-232 · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TL-895
2020
Completed Phase 1
~10

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 56 days

Who is running the clinical trial?

Kartos Therapeutics, Inc.Lead Sponsor
13 Previous Clinical Trials
1,169 Total Patients Enrolled
3 Trials studying Primary Myelofibrosis
473 Patients Enrolled for Primary Myelofibrosis
Telios Pharma, Inc.Industry Sponsor
5 Previous Clinical Trials
376 Total Patients Enrolled
2 Trials studying Primary Myelofibrosis
219 Patients Enrolled for Primary Myelofibrosis

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Cohort 3 is made up of patients who are intolerant to JAK inhibitor treatment.
The first group of people, Cohort 1, and the second group of people, Cohort 2, both responded positively to treatment with a JAK inhibitor.
The person has a confirmed diagnosis of primary MF, post-PV MF, or post-ET MF.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 30th, 2021

Last Reviewed: October 31st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.